VolitionRX logo

VNRX - VolitionRX Share Price

$3.1 -0.0  -0.3%

Last Trade - 01/04/20

Sector
Healthcare
Size
Small Cap
Market Cap £103.2m
Enterprise Value £92.7m
Revenue £13.8k
Position in Universe 3763rd / 6307
Bullish
Bearish
Unlock VNRX Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

VNRX Revenue Unlock VNRX Revenue

Net Income

VNRX Net Income Unlock VNRX Revenue

Normalised EPS

VNRX Normalised EPS Unlock VNRX Revenue

PE Ratio Range

VNRX PE Ratio Range Unlock VNRX Revenue

Dividend Yield Range

VNRX Dividend Yield Range Unlock VNRX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
VNRX EPS Forecasts Unlock VNRX Revenue
Profile Summary

VolitionRx Limited is a clinical-stage life sciences company. The Company is focused on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The Company has developed approximately 30 blood-based assays to detect specific biomarkers that can be used individually or in combination to generate a profile, which forms the basis of a test for a particular cancer or disease. The Company's Nucleosomics biomarker platform is a technology that is used for a range of cancers. The Company is developing Nucleosomics tests for various cancers, including colorectal, pancreatic, lung and aggressive prostate. The Company's NuQ blood assays fall into over five types, which include NuQ-X, NuQ-V, NuQ-M, NuQ-A and NuQ-T. It has developed approximately two blood assays in the NuQ-X family to detect the presence of cancer by detecting nucleosomes containing specific nucleotides.

Directors
Last Annual December 31st, 2019
Last Interim December 31st, 2019
Incorporated September 24, 1998
Public Since February 6, 2015
No. of Shareholders: 153
No. of Employees: 50
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index
Exchange NYSE MKT
Shares in Issue 41,204,685
Free Float (0.0%)
Eligible for
ISAs
SIPPs
VNRX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for VNRX
Upcoming Events for VNRX
Wednesday 6th May, 2020 Estimate
Q1 2020 VolitionRX Ltd Earnings Release
Friday 12th June, 2020 Estimate
VolitionRX Ltd Annual Shareholders Meeting
Tuesday 11th August, 2020 Estimate
Q2 2020 VolitionRX Ltd Earnings Release
Similar to VNRX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.